Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)

NCT02279173 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02279173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02279173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
December 10, 2014
Completion date
August 8, 2019
Enrollment
203 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia